| Induction FLOT With CROSS CRT for Esophageal Cancer (NCT04028167) | University of Colorado, Denver | 2020-04-08 |
| Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas (NCT03722108) | UNICANCER | 2019-02-07 |
| Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas (NCT04773769) | Auxilio Mutuo Cancer Center | 2018-11-07 |
| Perioperative Chemo and Pembrolizumab in Gastric Cancer (NCT02918162) | Gulam Manji | 2017-11-25 |
| Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA (NCT03307941) | Jules Bordet Institute | 2017-07-20 |
| Resilience and Exercise in Advanced Cancer Treatment (NCT02680990) | Milton S. Hershey Medical Center | 2015-12-01 |
| FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer (NCT02485834) | Alliance for Clinical Trials in Oncology | 2015-11-12 |
| A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer (NCT02443324) | Eli Lilly and Company | 2015-07-29 |
| C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer (NCT02344810) | Eastern Cooperative Oncology Group | 2015-03-06 |
| 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer (NCT01939275) | City of Hope Medical Center | 2014-11-19 |
| Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery (NCT02234180) | Academic and Community Cancer Research United | 2014-09-01 |
| A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab (NCT02013154) | Leap Therapeutics, Inc. | 2014-05-05 |
| FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (NCT02037048) | Case Comprehensive Cancer Center | 2014-02-10 |
| Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH (NCT01855854) | Betta Pharmaceuticals Co., Ltd. | 2013-05-01 |
| Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery (NCT01612546) | City of Hope Medical Center | 2012-11-01 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery (NCT01705340) | National Cancer Institute (NCI) | 2012-09-01 |
| S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer (NCT01498289) | SWOG Cancer Research Network | 2012-02-01 |
| Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer (NCT01231399) | City of Hope Medical Center | 2012-02-01 |
| Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction (NCT01523015) | Medical University of Lublin | 2012-01-01 |
| Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach (NCT01472029) | AIO-Studien-gGmbH | 2011-12-01 |
| A Survivorship Care Plan for Gynaecological Cancer Patients (NCT01582906) | Royal Marsden NHS Foundation Trust | 2011-08-01 |
| Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) (NCT01395537) | Case Comprehensive Cancer Center | 2011-08-01 |
| PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy (NCT01333033) | Alliance for Clinical Trials in Oncology | 2011-07-01 |
| Validation of a Nutrition Screening Tool (NCT01851928) | Royal Marsden NHS Foundation Trust | 2011-07-01 |
| Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction (NCT01360086) | Federation Francophone de Cancerologie Digestive | 2011-06-01 |
| Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer (NCT01212822) | Fox Chase Cancer Center | 2011-04-27 |
| Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer (NCT01307956) | University of Nebraska | 2011-02-28 |
| Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer (NCT01260701) | National Cancer Institute (NCI) | 2011-01-01 |
| Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer (NCT01123473) | European Organisation for Research and Treatment of Cancer - EORTC | 2010-12-01 |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer (NCT01178944) | Roswell Park Cancer Institute | 2010-09-01 |
| Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer (NCT01216813) | Royal Marsden NHS Foundation Trust | 2010-08-01 |
| Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery (NCT01107639) | Swiss Cancer Institute | 2010-05-27 |
| Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction (NCT00938470) | Alliance for Clinical Trials in Oncology | 2010-01-01 |
| Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer (NCT00982592) | National Cancer Institute (NCI) | 2009-09-01 |
| Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery (NCT00991952) | National Cancer Institute (NCI) | 2009-09-01 |
| Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction (NCT00891878) | Alliance for Clinical Trials in Oncology | 2009-08-01 |
| Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy (NCT01243398) | University of Oxford | 2009-03-01 |
| Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction (NCT00757172) | Alliance for Clinical Trials in Oncology | 2009-01-01 |
| Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction (NCT00732745) | Case Comprehensive Cancer Center | 2008-10-01 |
| A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery (NCT01183559) | Fox Chase Cancer Center | 2008-08-07 |
| Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer (NCT00978549) | Cambridge University Hospitals NHS Foundation Trust | 2008-04-01 |
| Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer (NCT00607594) | National Cancer Institute (NCI) | 2008-01-01 |
| Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction (NCT01561014) | Wake Forest University Health Sciences | 2007-04-01 |
| Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer (NCT00253370) | National Cancer Institute (NCI) | 2005-10-01 |
| Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (NCT01640782) | Mario Negri Institute for Pharmacological Research | 2005-02-01 |
| Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (NCT00084604) | National Cancer Institute (NCI) | 2004-04-01 |
| Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma (NCT00084617) | National Cancer Institute (NCI) | 2004-03-01 |
| A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer (NCT00064259) | National Cancer Institute (NCI) | 2003-06-01 |
| Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach (NCT00061932) | National Cancer Institute (NCI) | 2003-04-01 |
| Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer (NCT00963092) | Cancer Research UK | 2002-08-01 |
| Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer (NCT00045526) | National Cancer Institute (NCI) | 2002-06-01 |
| Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors (NCT04681248) | Leap Therapeutics, Inc. | |